Background: Pediatric multidrug-resistant tuberculosis (MDR-TB) remains a major public health concern in low- and middle-income countries, where bacteriologic confirmation is often difficult and long-term follow-up is challenging. Data describing the clinical characteristics and outcomes of children with MDR-TB in the Philippines are limited.
Objectives: To describe the demographic, clinical, diagnostic, and treatment outcome profiles of pediatric patients diagnosed with MDR-TB at the Philippine Children’s Medical Center (PCMC) from 2021 to 2025.
Methods: A retrospective descriptive review was conducted among children 0–18 years diagnosed with MDR-TB from January 2021 to August 2025. Data were obtained from the PCMC TB-DOTS electronic registry and medical records. Variables included age, sex, comorbidities, prior TB treatment, diagnostic modality, and treatment outcomes based on the National TB Control Program definitions. Descriptive statistics were used.
Results: Twenty-two patients were included with a mean age of 9.9 ± 5.3 years and equal sex distribution. Common comorbidities were respiratory diseases (54.5%) and malnutrition (50%). Previous TB treatment was incomplete or interrupted in 59.1% of cases. Most patients (81.8%) were diagnosed clinically, while only 18.2% had bacteriologic confirmation via GeneXpert MTB/RIF; none underwent culture or drug-susceptibility testing. Presenting symptoms included fever (77.3%), weight loss (68.2%), and cough (40.9%). Treatment outcomes showed 22.7% completed therapy, 4.5% achieved treatment success, 9.1% had treatment failure, and 18.2% died. Nearly half (45.5%) were still on treatment or not yet evaluated. Documentation of latent TB infection and HIV screening was limited.
Conclusion: Pediatric MDR-TB at our center was predominantly clinically diagnosed with low bacteriologic confirmation and suboptimal treatment outcomes. High rates of malnutrition and respiratory comorbidities further complicated management. Strengthening access to molecular and culture-based diagnostics, routine LTBI and HIV screening, standardized documentation, and robust follow-up systems are essential to improve outcomes in children with MDR-TB.

